Janssen receives positive CHMP opinion for SPRAVATO® (ESKETAMINE) nasal spray
Janssen announced the CHMP of the EMA has recommended approval for SPRAVATO®(esketamine)nasal spray,in combinationwith a selective serotonin reuptake inhibitor or serotonin and norepinephrine reuptake inhibitor, for adults living with treatment-resistant major depressive disorder. October 18, 2019